DURHAM, N.C., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it has completed its debt tender offer (the “Tender Offer”) described in the Offer to Purchase dated October 20, 2025 by purchasing $75,743,000 in aggregate of the Company's outstanding 7.500% Senior Secured Notes due 2030 (CUSIP No. 34965K AA5 (Rule 144A); U31685 AA5 (Reg S)) (each, a “Note” and collectively, the “Notes”). The Tender Offer to repurchase of a portion of the Notes satisfied a requirement relating to the Company's divestiture of its Fortrea Patient Access and Endpoint Clinical businesses completed in June 2024. Fortrea's purchase of the tendered Notes on November 21, 2025, reduced the principal outstanding on the Notes from $570,000,000 to $494,257,000.